



Press release

Half-yearly report on the liquidity contract with TP ICAP (Europe) SA

Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on December 31, 2025:

- Number of shares: 63,024
- Cash balance: 250,951.67 €

During the 2nd half of 2025, a total of :

PURCHASE	437,203 shares	1,389,323.53 €	369 transactions
SALE	536,477 shares	1,560,333.66 €	502 transactions

As a reminder, at the half-yearly balance sheet dated June 30, 2025, the following assets were included in the liquidity account:

- Number of shares: 162,298 shares
- Cash balance: 86,279.52 €

When the liquidity contract was set up, the following resources were made available:

- Number of shares: 131,000 shares
- Cash balance: 40,801.20 €

ANNEX H2 2025

ABNX FP	Purchases			Sales		
	Number of transactions	Number of shares	Capital in EUR	Number of transactions	Number of shares	Capital in EUR
Total	369	437 203	1 389 323,53	502	536 477	1 560 333,66
20250701	1	1	1,19	3	2 902	3 492,92
20250702	1	1	1,21	2	224	271,49
20250703	2	2 271	2 707,06	2	2	2,44
20250704	1	1	1,21	1	1	1,21
20250707	1	1	1,21	1	1	1,21
20250708	1	1	1,21	1	1	1,21
20250709	1	1	1,19	1	1	1,19
20250710	1	1	1,21	1	1	1,21
20250711	1	1	1,21	2	1 781	2 172,81
20250714	1	1	1,22	2	32	39,17
20250715	1	1	1,23	1	1	1,23
20250716	1	1	1,23	1	1	1,23
20250717	1	1	1,23	1	1	1,23
20250718	1	1	1,23	2	2 211	2 746,05
20250721	1	1	1,26	2	153	193,08
20250722	1	1	1,25	1	1	1,25
20250723	1	1	1,26	5	8 691	11 045,44
20250724	1	1	1,30	5	12 291	16 286,42
20250725	3	3 681	4 900,69	4	7 551	10 418,87
20250728	1	1	1,39	11	30 861	44 685,19
20250729	3	4 551	6 939,43	11	23 541	38 883,67
20250730	7	16 231	28 984,31	1	1	1,85
20250731	11	26 661	43 396,07	1	1	1,75
20250801	5	8 061	12 270,79	5	8 409	13 719,53
20250804	1	1	1,63	9	22 381	37 265,25
20250805	3	3 082	5 176,63	5	8 621	15 063,56
20250806	1	1	1,73	4	3 162	5 499,94
20250807	6	13 921	22 958,52	1	1	1,74
20250808	6	11 283	17 654,04	1	1	1,61
20250811	1	1	1,60	6	16 139	26 625,15
20250812	1	1	1,67	1	1	1,67
20250813	1	1	1,82	5	8 561	15 592,26
20250814	2	3 041	5 552,91	6	9 801	18 728,69
20250815	3	4 441	8 081,58	3	2 471	4 694,90
20250818	1	1	1,85	5	7 381	13 761,45
20250819	1	1	1,90	5	6 761	13 001,38
20250820	1	1	1,92	2	1 041	1 994,56
20250821	1	1	1,91	4	4 111	7 922,95
20250822	1	1	1,92	11	16 261	33 277,95
20250825	1	1	2,15	11	12 341	28 080,35
20250826	9	29 511	61 139,20	4	2 261	5 134,54

20250827	1	1	2,06	11	15 911	35 190,61
20250828	1	1	3,00	11	12 281	36 843,00
20250829	3	4 451	12 561,07	11	9 471	29 076,87
20250901	1	1	3,58	11	8 281	30 366,58
20250902	11	21 591	88 354,20	5	2 251	10 356,40
20250903	7	11 071	39 819,29	3	1 321	5 059,59
20250904	1	1	3,67	9	9 931	37 813,67
20250905	6	9 721	35 058,97	2	146	554,77
20250908	10	17 481	58 490,32	1	1	3,67
20250909	2	1 071	3 288,01	3	4 301	15 058,31
20250910	5	4 381	15 945,72	2	1 111	4 210,62
20250911	1	1	3,69	10	16 481	63 688,84
20250912	2	1 741	6 624,56	5	5 471	21 652,16
20250915	1	1	4,05	7	7 691	31 674,55
20250916	2	1 951	7 999,10	1	1	4,10
20250917	3	2 701	10 539,33	1	1	3,93
20250918	5	7 061	26 397,84	4	1 418	5 548,50
20250919	1	1	3,98	4	3 861	15 370,43
20250922	4	4 521	16 592,07	4	3 551	13 974,17
20250923	1	1	3,90	2	741	2 897,30
20250924	2	2 151	8 238,42	5	4 321	17 201,42
20250925	3	2 981	11 542,61	2	701	2 775,91
20250926	8	11 691	42 489,70	1	1	3,80
20250929	1	1	3,65	1	1	3,65
20250930	6	8 666	27 625,95	3	1 801	6 087,45
20251001	1	1	3,30	5	5 201	17 679,60
20251002	4	4 031	14 056,97	1	1	3,57
20251003	1	1	3,50	2	961	3 363,50
20251006	4	3 981	13 425,80	3	1 941	6 793,50
20251007	3	2 571	8 573,54	1	1	3,34
20251008	1	1	3,36	5	6 041	20 796,66
20251009	3	2 661	9 086,46	3	1 901	6 672,66
20251010	4	3 981	13 624,80	1	1	3,50
20251013	1	1	3,31	6	7 491	25 790,01
20251014	4	4 201	14 399,15	1	1	3,45
20251015	1	1	3,36	7	9 231	32 617,96
20251016	2	694	2 415,21	3	1 681	6 014,02
20251017	3	2 941	10 387,78	1	1	3,58
20251020	5	6 851	23 172,65	5	5 071	18 272,75
20251021	6	9 251	29 989,79	1	1	3,39
20251022	1	1	3,60	11	16 811	60 519,60
20251023	4	4 571	16 671,75	5	4 621	17 702,95
20251024	1	1	3,80	10	11 221	44 748,50
20251027	4	3 720	14 789,73	10	8 961	38 919,58
20251028	1	1	4,55	11	9 141	43 405,35
20251029	9	17 141	80 006,34	5	2 491	12 793,24
20251030	7	10 551	45 404,28	1	1	4,48
20251031	5	6 161	25 646,05	5	4 551	20 164,05
20251103	3	2 641	10 780,86	5	4 691	20 122,46

20251104	3	2 791	11 169,73	6	5 701	24 018,23
20251105	6	8 891	35 906,45	1	1	4,15
20251106	1	1	3,93	10	12 201	50 259,43
20251107	3	4 101	17 236,46	5	3 771	16 503,76
20251110	4	4 481	18 568,60	2	681	2 914,60
20251111	1	1	4,18	4	2 941	12 445,78
20251112	7	10 501	42 742,65	5	4 111	18 133,25
20251113	3	2 821	11 148,77	3	1 581	6 434,67
20251114	2	291	1 155,34	4	1 631	6 663,64
20251117	1	1	4,28	5	4 631	19 850,73
20251118	3	2 871	11 949,27	1	1	4,17
20251119	1	1	4,22	3	1 541	6 572,62
20251120	3	2 821	11 769,34	3	1 481	6 361,14
20251121	1	1	4,35	9	9 551	42 161,65
20251124	4	4 901	20 063,60	1	1	4,20
20251125	1	1	4,18	5	4 061	17 465,18
20251126	5	6 881	29 098,30	1	1	4,30
20251127	3	2 224	9 072,46	1	1	4,08
20251128	2	2 111	8 528,48	1	1	4,08
20251201	4	4 241	17 022,46	1	1	4,06
20251202	4	4 071	15 973,93	1	1	4,03
20251203	5	6 181	23 005,50	1	1	3,80
20251204	1	1	3,79	5	5 881	22 765,19
20251205	1	1	3,91	3	1 851	7 265,61
20251208	1	1	3,90	1	1	3,90
20251209	3	2 671	10 208,65	2	891	3 483,75
20251210	4	3 951	14 989,23	1	1	3,83
20251211	4	3 851	14 083,72	1	1	3,72
20251212	4	3 721	13 236,49	2	1 011	3 710,29
20251215	1	1	3,53	2	1 051	3 731,03
20251216	4	3 721	12 713,02	1	1	3,42
20251217	9	12 721	39 905,26	1	1	3,16
20251218	1	1	3,20	6	9 481	31 218,90
20251219	1	1	3,41	6	8 501	29 709,51
20251222	5	5 991	20 522,54	1	1	3,54
20251223	1	1	3,40	4	4 381	15 331,30
20251224	1	1	3,49	3	2 111	7 462,79
20251225	0	0	0,00	0	0	0,00
20251226	0	0	0,00	0	0	0,00
20251229	3	2 591	8 925,20	2	1 011	3 568,80
20251230	2	1 831	6 408,52	5	6 101	22 274,12
20251231	1	1	3,67	6	7 291	27 527,77

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I-based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

Contacts :

ABIONYX Pharma

infos@abionyx.com